Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
crawled date : 2022 - 10 - 27 source : Www.biospace.com save search
Bio-Rad Reports Third-Quarter 2022 Financial Results
Published: 2022-10-27 (Crawled : 23:00) - biospace.com/
BIO | $279.73 -0.46% 0.0% 290K
|
Health Technology
|
| O: -0.04%
H: 0.27%
C: -2.26%
financial results
Ultragenyx to Host Conference Call for Third Quarter 2022 Financial Results and Corporate Update
Published: 2022-10-27 (Crawled : 23:00) - biospace.com/
RARE | News F | $42.37 -2.33% -2.38% 680K
|
Health Technology
|
| O: 1.1%
H: 0.67%
C: -2.67%
conference financial update
Iridex to Report Third Quarter 2022 Financial Results on November 10, 2022
Published: 2022-10-27 (Crawled : 23:00) - biospace.com/
IEX | $227.04 0.42% 0.0% 240K
|
Producer Manufacturing
|
| O: 0.66%
H: 0.56%
C: -1.69%
IRIX | $2.95 -2.32% -2.37% 50K
|
Health Technology
|
| O: 3.21%
H: 0.0%
C: -5.59%
report financial results
Clovis Oncology Presents Data from TRITON3 Phase 3 Trial of Rubraca® (rucaparib) at the 29th Annual Prostate Cancer Foundation Scientific Retreat
Published: 2022-10-27 (Crawled : 23:00) - biospace.com/
CLVS | $0.0812 -3.94%
|
Health Technology
|
| O: -0.94%
H: 1.9%
C: -0.95%
rubraca trial cancer prostate cancer
Travere Therapeutics Reports Third Quarter 2022 Financial Results
Published: 2022-10-27 (Crawled : 22:00) - biospace.com/
TVTX | $5.73 -1.21% -1.22% 950K
|
Health Technology
|
| O: 2.16%
H: 1.1%
C: -1.06%
therapeutics financial results
Regulus Therapeutics Announces Poster Presentation at ASN Kidney Week 2022
Published: 2022-10-27 (Crawled : 22:00) - biospace.com/
RGLS | $2.13 -4.05% -4.23% 220K
|
Health Technology
|
| O: 1.9%
H: 0.0%
C: -2.48%
kidney week therapeutics presentation
Acutus Medical to Announce Third Quarter 2022 Financial Results
Published: 2022-10-27 (Crawled : 22:00) - biospace.com/
AFIB | $0.167 -4.3% -4.49% 400K
|
Health Technology
|
| O: -1.25%
H: 2.03%
C: -5.7%
financial results
Geron to Announce Third Quarter 2022 Financial Results on November 3, 2022
Published: 2022-10-27 (Crawled : 22:00) - biospace.com/
GERN | $3.69 -1.07% -1.08% 8.2M
|
Health Technology
|
| O: 1.67%
H: 0.82%
C: -5.35%
financial results
Sangamo Therapeutics Announces Third Quarter 2022 Conference Call and Webcast
Published: 2022-10-27 (Crawled : 22:00) - biospace.com/
SGMO | $0.5143 6.02% 5.68% 1M
|
Health Technology
|
| O: 0.46%
H: 1.83%
C: -1.6%
conference therapeutics
Pulse Biosciences Schedules Third Quarter 2022 Financial Results Conference Call for November 10, 2022
Published: 2022-10-27 (Crawled : 22:00) - biospace.com/
PLSE | $7.2 -2.17% -2.22% 180K
|
Health Technology
|
| O: 0.42%
H: 2.66%
C: -5.42%
conference financial
Veracyte to Participate in the Credit Suisse 31st Annual Healthcare Conference
Published: 2022-10-27 (Crawled : 22:00) - biospace.com/
VCYT | $19.43 1.2% 1.18% 1.4M
|
Health Technology
|
| O: 1.42%
H: 1.4%
C: -0.64%
conference
Chimerix to Report Third Quarter 2022 Financial Results and Provide an Operational Update on November 3, 2022
Published: 2022-10-27 (Crawled : 22:00) - biospace.com/
CMRX | $0.8844 -5.14% -5.42% 430K
|
Health Technology
|
| O: 1.68%
H: 0.0%
C: -2.75%
report financial update results
Oncocyte to Announce Third Quarter 2022 Financial Results
Published: 2022-10-27 (Crawled : 22:00) - biospace.com/
OCX | News J | $2.495 -2.54% -2.61% 50K
|
Health Technology
|
| O: -1.31%
H: 2.58%
C: -12.35%
financial results
Edgewise Therapeutics Announces Initiation of LYNX Phase 2 Clinical Trial of EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (DMD)
Published: 2022-10-27 (Crawled : 22:00) - biospace.com/
EWTX | $15.23 -1.42% -1.44% 540K
|
Manufacturing
|
| O: 1.21%
H: 0.0%
C: -6.88%
edg-5506 treatment trial therapeutics duchenne
Adaptimmune to Report Q3 2022 Financial and Business Updates on Tuesday, November 8, 2022
Published: 2022-10-27 (Crawled : 20:00) - biospace.com/
ADAP | $0.97 7.97% 7.38% 1.5M
|
Health Technology
|
| O: 1.49%
H: 2.94%
C: 0.74%
report financial
Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights
Published: 2022-10-27 (Crawled : 18:00) - biospace.com/
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: -0.78%
H: 0.16%
C: -3.13%
biotech conference financial results
KAZIA'S PAXALISIB DEMONSTRATES POSITIVE MONOTHERAPY EFFICACY SIGNALS IN PRECLINICAL MODELS OF MELANOMA
Published: 2022-10-27 (Crawled : 18:00) - biospace.com/
KZIA | $0.379 9.47% 8.65% 300K
|
Health Technology
|
| O: 24.14%
H: 4.76%
C: -21.43%
melanoma preclinical paxalisib positive
Omega Therapeutics Announces First Patient Dosed in Landmark MYCHELANGELO™ I Trial of OTX-2002 in Hepatocellular Carcinoma and Other Solid Tumor Types Associated with the MYC Oncogene
Published: 2022-10-27 (Crawled : 18:00) - biospace.com/
OMGA | $2.4 -0.83% -0.83% 400K
|
|
| O: 2.16%
H: 5.56%
C: -7.05%
otx-2002 trial therapeutics
Urovant Sciences Announces Publication of Pharmacokinetic Data on GEMTESA® (Vibegron 75mg) Administered as an Intact or Crushed Tablet
Published: 2022-10-27 (Crawled : 17:00) - biospace.com/
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
|
| O: -0.07%
H: 0.0%
C: -0.26%
gemtesa sciences publication
Neovasc to Report Third Quarter Financial Results on November 10, 2022
Published: 2022-10-27 (Crawled : 17:00) - biospace.com/
NVCN | $30.03 1.66% -2.02% 0
|
Health Technology
|
| O: -1.27%
H: 0.36%
C: 0.0%
report financial results
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.